AstraZeneca (AZN.US) suspends investment plans in the UK and receives another downgrade in ratings from institutions.

According to the Wise Financial APP, Handelsbanken, a Swedish commercial bank, has downgraded AstraZeneca (AZN.US) from "buy" to "hold", stating that it believes the company's goal of reaching total revenue of $80 billion by 2030 is too optimistic. It has been reported that the company has suspended major investments in its domestic market. This largest listed company in the UK has become the latest pharmaceutical company to reduce its operations in the country. A company spokesperson said last Friday evening that it has suspended a 200 million (approximately $272.12 million) investment plan at its Cambridge research center, which is a blow to the UK government.